Table 1.
Demographic and clinical characteristics of all study participants at baseline.
| ALS C9– | ALS C9+ | PLS | PMA | CON | p-value | |
|---|---|---|---|---|---|---|
| n (n follow-up) | 108 (64) | 26 (18) | 28 (18) | 56 (41) | 114 (54) | |
| Follow-up interval, m (median, range) | 4.9c (3.0–9.8) | 5.4c (3.0–10.0) | 6.8c (3.2–85.9) | 5.5c (3.0–59.0) | 14.7 (4.3–50.8) | 0.009 |
| Gender (%) | 0.007 | |||||
| Male | 59 (54.6) | 17 (65.4) | 17 (60.7) | 46 (82.1) | 63 (55.3) | |
| Female | 49 (45.4) | 9 (34.6) | 11 (39.3) | 10 (17.9) | 51 (44.7) | |
| Age at 1st MRI (median, range) | 64.6 (30.6–80.5) | 59.7 (40.6–67.0) | 60.2 (36.1–78.3) | 63.1 (22.6–80.1) | 65.0 (30.8–79.4) | 0.027 |
| Site of onset (%) | <0.001 | |||||
| Bulbar | 30 (27.8) | 5 (19.2) | 3 (10.7) | 0 (0.0) | – | |
| Spinal | 78 (72.2) | 21 (80.8) | 25 (89.3) | 56 (100) | – | |
| Disease durationa, b (median, range) | 14.4 (2.9–174.4) | 11.5 (3.3–68.3) | 90.6 (23.5–224.9) | 20.3 (4.6–467.4) | – | <0.001 |
| ALSFRS-R score (median, range) | 40 (23–47) | 41 (30–47) | 39 (28–44) | 41.5 (25–48) | – | 0.027 |
a
Disease duration was measured from disease onset until date of the first MRI in months.
b
Diagnosis of PLS and PMA was given after 4 years, but prior (baseline) scans were included in analyses.
c
Denotes characteristics that significantly differ (p < .05) between a patient group and their matched control group. The column of p-values denotes significant differences between the patient groups.